157 related articles for article (PubMed ID: 16217853)
1. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities.
Braun TM
Stat Med; 2006 Jun; 25(12):2071-83. PubMed ID: 16217853
[TBL] [Abstract][Full Text] [Related]
2. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
3. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
4. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of dose-finding studies to observation errors.
Zohar S; O'Quigley J
Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
[TBL] [Abstract][Full Text] [Related]
6. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
7. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
Yuan Z; Chappell R; Bailey H
Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
[TBL] [Abstract][Full Text] [Related]
8. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
9. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
Gönen M
Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of sequential dose-finding designs.
O'Quigley J
Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
[TBL] [Abstract][Full Text] [Related]
12. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
Yin G; Zheng S; Xu J
J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
[TBL] [Abstract][Full Text] [Related]
13. Retrospective robustness of the continual reassessment method.
O'Quigley J; Zohar S
J Biopharm Stat; 2010 Sep; 20(5):1013-25. PubMed ID: 20721788
[TBL] [Abstract][Full Text] [Related]
14. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
Huang B; Kuan PF
Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
[TBL] [Abstract][Full Text] [Related]
15. Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Andrillon A; Biard L; Lee SM
J Biopharm Stat; 2023 Jul; ():1-12. PubMed ID: 37496233
[TBL] [Abstract][Full Text] [Related]
16. Designs for phase I clinical trials with multiple courses of subjects at different doses.
Fan SK; Wang YG
Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
[TBL] [Abstract][Full Text] [Related]
17. Toxicity equivalence range design (TEQR): a practical Phase I design.
Blanchard MS; Longmate JA
Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
[TBL] [Abstract][Full Text] [Related]
18. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
19. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
Daimon T; Zohar S; O'Quigley J
Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
Mauguen A; Le Deley MC; Zohar S
Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]